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Cdc6p and the origin recognition complex (ORC) are essential for
assembly of a pre-replicative complex (preRC) at origins of replication,
before the initiation of DNA synthesis. In the absence of Cdc6p, cells
fail to initiate DNA replication and undergo a ‘‘reductional’’ mitosis,
in which the unreplicated chromosomes are randomly segregated to
the spindle poles. We show here that the cells harboring a mutation
in the essential Cdc6p Walker A-box arrest in late mitosis, probably at
anaphase. This cell cycle block requires either the three Cdc28p
phosphorylation sites within the N terminus of Cdc6p or a short
region (aa 8–17) that contains a Cy (Cyclin) interaction sequence.
These same two Cdc6p mutants that allow a reductional mitosis are
defective in binding Cdc28p kinase. In addition to Cdc6p, ORC also
binds to cyclin-dependent kinases (CDKs). Interestingly, Sic1p, a CDK
inhibitor protein, blocked the S phase-specific Cdc28p-Clb5p kinase
from interacting with ORC, but did not prevent the G1-specific
Cdc28p-Cln2p kinase–ORC interaction. We suggest that ORC, Cdc6p,
and Sic1p bind to different CDKs in a cell cycle-dependent manner to
temporally regulate events that (i) allow preRC formation after
mitosis, (ii) prevent mitosis before DNA replication can occur, and (iii)
promote initiation of DNA replication.
The initiation of DNA replication in Saccharomyces cerevisiaeand other eukaryotes is a cell cycle-regulated process requiring
the assembly of a pre-replicative complex (preRC) at origins of
DNA replication during G1 phase (1–4). The preRC contains
several conserved initiation proteins and assembles before DNA
synthesis (4). PreRC proteins include the origin recognition com-
plex (ORC) that binds to and marks replication origins throughout
the entire cell cycle, the Cdc6 protein (Cdc18 in Schizosaccharo-
myces pombe; ref. 5), the minichromosome maintenance (MCM)
helicase, and Cdt1 (6). Cdc6p is an unstable protein that interacts
with ORC and promotes loading of the six-subunit MCM complex
to origins in an ATP-dependent manner (7–15). Although not yet
identified in budding yeast, Cdt1 is also required for MCM binding
to chromatin (6). The preRC renders chromosomes competent for
initiation of DNA replication, but initiation does not occur because
cells have not yet committed to S phase. Both cyclin-dependent
protein kinases (CDKs; Cdc28p-Clb5p and -Clb6p) and Cdc7p-
Dbf4p are required for S phase commitment by activating origin
firing and promoting loading of Cdc45p (16–29).
Yeast Cdc28p interacts with two types of cyclins, the Cln and Clb
cyclins, to form an active CDK (30). The G1 cyclins, Cln1p and
Cln2p, control bud formation, spindle pole body duplication, and
one step in the initiation of DNA replication. The Cln-CDKs
promote DNA replication by allowing expression and activation of
the other type of CDK-cyclin, the B-type CDKs containing Clb5p
or Clb6p cyclins (31, 32). In late G1, the Clns promote degradation
of the B-type CDK inhibitor, Sic1p, and the initiation protein Cdc6p
(33–35). There are six CLB genes (CLB1-6) in budding yeast.
Clb5p- and Clb6p-dependent kinases promote origin activation in
a temporally controlled manner (36) and activation of origins by
loading Cdc45p (23), whereas Clb1–4p kinases act later in the cell
cycle, during G2 and M phase.
DNA replication is controlled by CDKs in at least two ways.
First, preRC assembly can only occur when CDKs are inactive,
thereby restricting preRC assembly to the period from mitotic
exit to late G1 (37–42). During this period, CDKs are kept
inactive by a functioning anaphase-promoting complex (APCy
cyclosome) and the presence of the CDK inhibitor Sic1p. The
APCycyclosome containing the adaptor Cdc20p promotes exit
from mitosis by ubiquitinating the anaphase inhibitor Pds1 and
Clb cyclins, such as Clb5p (43). The Cdc28p inhibitor Sic1p (p40)
inhibits the kinase activity of any Cdc28p-Clb cyclin until late G1
(44). Later in the cell cycle, when CDK activity is high during S,
G2, and early mitosis, assembly of the preRC cannot occur.
However, CDKs provide a second function because they are
required for origin activation in late G1 (37–39, 45). CDK
regulation of preRC assembly includes control of cell localiza-
tion of MCM proteins and stability or availability of initiation
regulatory proteins such as Sic1p and Cdc6p (34, 40–42). After
inhibition of APC and destruction of Sic1p, CDKs are activated
and promote loading of Cdc45p and other proteins at each origin
in a temporally regulated manner (23, 24, 46).
In addition to regulating the assembly of the preRC, cells also
have checkpoint mechanisms to coordinate progression from
one phase of the cell cycle to the next (47–50). Checkpoints act
to inhibit subsequent cell cycle events if there is a delay or error
in a preceding stage. For instance, the S phase checkpoint acts
to inhibit the metaphase to anaphase transition in budding yeast
when DNA damage or incomplete DNA replication occurs
during S phase. DNA damage or incomplete DNA replication is
sensed and results in the activation of the Mec1p and Rad53p
kinases that mediate repair and cell cycle arrest. Johnston and
colleagues (51) have also described a G1–M phase checkpoint
that operates in budding yeast to prevent mitosis in the absence
of the initiation of DNA replication. This less well characterized
pathway is independent of the Mec1p checkpoint kinase that
mediates the inhibition of mitosis in response to incomplete
DNA replication or damage. Furthermore, not all yeast strains
have retained this checkpoint mechanism. The G1–M checkpoint
is dominant in heterozygous diploids, suggesting that some
standard yeast strains have mutations in this pathway.
Depletion of Cdc6p prevents replication initiation and results
in a reductional mitosis in which cells randomly segregate their
unreplicated chromosomes (8). Under these circumstances, the
G1–M checkpoint is not operating. Paradoxically, we described
a nonfunctional cdc6 mutant (in the same strain background)
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that prevented mitosis in the absence of DNA replication (12).
Cdc6p is predicted to be an ATP binding protein and a mutant
that changed a conserved lysine to glutamate (K114E) in the
Walker A box was not able to initiate DNA replication or load
the MCM proteins at the origin. So, in contrast to depletion of
Cdc6p, cells expressing cdc6(K114E) (hereafter referred to as
cdc6KE) did not pass through mitosis, suggesting that the inhi-
bition of mitosis required Cdc6p itself. The inhibitory activity
was mapped to the N-terminal 50 aa of Cdc6p, a region that is
dispensable for its essential role in initiation (12).
Cdc18, the fission yeast homologue of Cdc6p, is required for the
initiation of DNA replication (5) and also inhibits passage through
mitosis when the protein is overproduced (52, 53). Like Cdc6p,
Cdc18 is an unstable protein. Cdc18 contains six consensus CDK
phosphorylation sites (five within the N terminus) that mediate its
turnover, because mutation of these sites increases Cdc18p stability
(54). Inhibition of B-type CDK activity also increased the stability
of Cdc18. Like Cdc6p, which binds Cdc28 cyclin (55), Cdc18
interacts through its N terminus with the CDK subunit Cdc2
associated with the B-type cyclins (Cdc13 and Cig2; ref. 56).
Increasing Cdc18 levels through overproduction leads to repeated
rounds by DNA synthesis by promoting replication re-initiation.
This may reflect an inhibition of mitotic CDK activity through
direct binding and by promotion of new initiation events when
Cdc18 is greatly overproduced.
Here we show that the ability to inhibit mitosis is abrogated by
one of two separate mutations within the N terminus of Cdc6p.
The first changes the three Cdc28 consensus phosphorylation
sites at T7, T23, and S43 to alanine (TTS). The second, by
deleting a 10-aa region (D8–17) containing a match to the Cy
(Cyclin) motif. The Cy motif is found in other eukaryotic
proteins and mediates binding to CDK-cyclins (57–60). The
ability of Cdc6p to inhibit mitosis is also correlated with binding
to Cdc28p. A genetic analysis indicates that increasing B-type
CDK activity can overcome the mitotic arrest of the cdc6KE
mutant. The inhibition of mitosis is independent of RAD53,
indicating that it is independent of the G1–S or S phase check-
point pathways. These results suggest that the N terminus of
Cdc6p has a function during mitosis and might be involved in the
G1–M checkpoint pathway. We also suggest that Cdc6p, together
with Sic1p and the APCycyclosome, antagonizes CDK activity in
late mitosis to early G1, perhaps directly at origins of replication.
Finally, we demonstrate that Sic1p, in addition to regulating
CDK activity, controls substrate accessibility.
Materials and Methods
Strains and Plasmids. Genetic manipulation and transformation of
yeast was done by standard techniques (61, 62). All S. cerevisiae
strains were derivatives of W303 (63). Mutations in CDC6 were
introduced by using site-directed mutagenesis of single-stranded
uracil-containing phagemid DNA. After sequencing a restriction
fragment containing the mutation, the mutations were transferred
to pMW71 (pRS415-CDC6) for testing complementation and into
pMW333 (pRS405-cdc6KE) for integration into the LEU2 locus as
described (12). The plasmids pWS945 (pGAL-CLB5) and yCpG2
(pGAL-CLN1) were obtained from B. Futcher (Cold Spring Har-
bor Laboratory, Cold Spring Harbor, NY). pJA92 (RAD53 URA3)
was from S. Elledge (Baylor College of Medicine, Houston).
pMW479 (pGAL-CDC4) was constructed by cloning a BamHI-
SacI PCR fragment using genomic DNA as template into the
pGAL expression plasmid pVF1. CDC4 was entirely sequenced to
verify that it was wild type. Galactose-dependent induction of
Cdc4p was determined by Western blot using rabbit polyclonal
antibodies against Cdc4p (from M. Goebl, Indiana University
School of Medicine, Bloomington, IN).
Immunoprecipitation of HA-CDC6 and Associated Proteins. Baculo-
virus transfer vectors were constructed in pAcSG2 (PharMin-
gen) to encode HA-HIS6-CDC6 wild type (pMW44) and the
TTS (pMW475) and D8–17 (pMW476) derivative mutants. An
NcoI site was introduced at the N terminus of CDC6 and the
epitope tag was inserted into this site. Recombinant viruses were
constructed by using the BaculoGold system as described (7). The
viruses were separately infected into 2 3 107 Sf9 cells on 10-cm
plates and harvested after 40 h at 27°C. The multiplicity of infection
was adjusted so that the HA-HIS6-Cdc6 proteins were produced
equally. Sf9 cells were lysed in 1 ml Sf9 lysis buffer (10 mM TriszHCl
(pH 7.5)y0.2% Nonidet P-40y1 mM EDTAy1 mM EGTA) con-
taining 150 mM NaCl and a mixture of protease and phosphatase
inhibitors. After centrifugation at 14,000 rpm, the soluble fraction
was taken and the NaCl concentration was adjusted to 0.5 M.
Monoclonal antibody 12CA5 coupled to protein A Sepharose beads
(10 ml bed volume) was added to the lysate and mixed at 4°C for 2 h.
Antibody beads were collected and washed four times in the same
buffer containing 500 mM NaCl and then once in same buffer
containing 150 mM NaCl. W303 was grown to an OD600 5 0.5,
harvested, washed once with water, and resuspended in 2 ml of yeast
Nonidet P-40 lysis buffer (20 mM TriszHCl (pH 7.5)y150 mM
NaCly1 mM EGTAy0.5% Nonidet P-40) containing a mixture of
protease and phosphatase inhibitors. Bead-beated yeast cell ex-
tracts were made as described (25) and equal volumes of yeast
extract (500 ml) were added to each of the Sf9 immunoprecipitates.
After a further 2-h incubation at 4°C, the beads were washed four
times in the same buffer, resuspended in protein sample buffer, and
separated on SDSy12.5% PAGE gels. These gels were silver-
stained to visualize Cdc6p or blotted and probed with rabbit
polyclonal antibodies directed against Cdc28p (1:2000 from B.
Futcher) to detect associated proteins. Control beads from wild-
type Sf9 cell lysates (i.e., not charged with HA-HIS6-Cdc6p) did not
immunoprecipitate Cdc28p (data not shown).
Other Methods. Tubulin staining (64), f luorescence-activated cell
sorter (FACS) analysis and chromatin binding experiments to
look at Orc6p phosphorylation were carried out as described
(65). Baculoviruses expressing ORC (66) and Cdc28p-Clb5p (67)
have been described. The Sic1p baculovirus was obtained from
Mike Tyers (University of Toronto), and the Cln2p baculovirus
from Ray Deschaies (California Institute of Technology, Pasa-
dena). Baculovirus transfer vectors to express Clb1p and Clb6p
were constructed by cloning the HindIII-NheI CLB1 and CLB6
restriction fragments into pAcPK31 (7) to give pMW10 and
pMW11, respectively. Baculoviruses were constructed by using
the BaculoGold system (PharMingen). For the kinase assays in
Fig. 6C, the immunoprecipitates (IPs) were washed in 50 mM
TriszHCly10 mM MgCl2 and then resuspended in 10 ml 50 mM
TriszHCly10 mM MgCl2y1 mM ATP containing 1 mg histone H1
and 10 mCi (1 Ci 5 37 GBq) [g-32P]ATP. The reactions were
incubated for 10 min at 30°C and then separated on SDSy12.5%
PAGE gels.
Results
Cells Expressing cdc6KE Arrest in G2yM in a RAD53-Independent Manner.
Depletion of Cdc6p resulted in a failure to initiate DNA replication
and after a period, a ‘‘reductional’’ mitosis occurred in which
unreplicated chromosomes formed spindle attachments and ran-
domly segregated to the two spindle poles (8). Subsequent cytoki-
nesis resulted in cell death because cells accumulated with frac-
tional (0.5C) DNA contents. The cdc6KE Walker A mutant also
failed to initiate DNA replication because it did not load the MCMs
onto chromatin; however, these cells did not undergo a reductional
mitosis, but arrested with a 1C DNA content (12).
To determine whether the cdc6KE mutation caused cells to
arrest in G1 or G2yM, we compared the morphology of cells
expressing this mutant form of Cdc6p with cells lacking any
Cdc6p. Cells expressing cdc6KE from its natural promoter and
wild-type CDC6 under control of the methionine repressible
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MET3 promoter were grown to early exponential phase. The
wild-type Cdc6p had a half-life of ’5 min and disappeared
rapidly after the addition of methionine to the medium (8). Cells
expressing only cdc6KE accumulated as large budded cells with a
1C DNA content and with long spindles (Fig. 1 A–C), indicating
that cells accumulated in mitosis, probably late anaphase, and
not in G1.
A trivial explanation for the mitotic arrest phenotype seen with
the cdc6KE mutant could be that this allele allowed initiation of
replication at a very small subset of origins. Such limited initiation
events could activate the RAD53-dependent G1yS or S phase
checkpoint response pathway that prevents mitosis when DNA
replication is blocked (47–49). We thought that RAD53 was not
likely to be involved in the CDC6-dependent mitotic arrest because
in the absence of DNA replication, sister chromatid cohesion is not
possible. It is thought that RAD53 inhibits the metaphase to
anaphase transition by inhibiting cleavage of Pds1p and Scc1p,
thereby preventing sister chromatid separation (68, 69). However,
to test whether this arrest was RAD53-dependent, the rad53-1
mutation was introduced into the cdc6KE strain and DNA content
was measured by FACS following shut off of the wild-type MET3-
CDC6. Two rad53-1 segregants from the cross were analyzed. One
of the cdc6KE rad53-1 strains (YB791) still arrested with a 1C DNA
content, but unexpectedly, a second cdc6KE rad53-1 strain (YB792)
underwent reductional mitosis (data not shown). Both cdc6KE
rad53-1 strains were transformed with a wild-type copy of RAD53
on an ARS-CEN plasmid. RAD53 reversed the hydroxyurea (HU)
sensitivity of both strains as expected; however, it had no effect on
the reductional mitosis of the YB792 strain. Therefore, the mitotic
block in the first cdc6KE strain was RAD53-independent. The
reductional mitosis seen in the second strain was also RAD53-
independent and must have been caused by an alteration at another
locus, consistent with previous findings that not all S. cerevisiae
strains have an intact G1–M checkpoint pathway (51).
One of the functions of a checkpoint response is to maintain cell
viability by delaying the cell cycle until the error in cell division
process is corrected. We tested whether the cdc6KE-dependent
arrest maintained cell viability by comparing the number of viable
cells over time following shut off of wild type MET3-CDC6 in the
cdc6KE mutant strain to the strain containing no additional CDC6.
Both strains lost viability at a similar rate to 5–10% after 5 h (Fig.
1D). This observation indicated that this arrest was not a true
checkpoint, because the entry into mitosis with unreplicated chro-
mosomes was a lethal event. The arrest more likely reflects some
function (besides MCM loading) that wild-type Cdc6p promotes
during mitosis, and this function is also required for the completion
of mitosis under these circumstances.
Inhibition of Mitosis Requires One of Two Sequences in Cdc6p. A
structure-function analysis was used to determine which of the
amino acids within the N terminus of Cdc6KEp were responsible for
the mitotic arrest in the absence of DNA replication. A series of
nested deletions beginning at the N terminus was created and after
introduction into cells, DNA content was determined by sampling
every hour for 5 h following shut-off of the wild-type CDC6 gene.
Deletion of the first eight amino acids had no effect on the mitotic
arrest, however, all subsequent deletions were unable to maintain
an arrest and accumulated with 0.5C DNA content (summarized in
Fig. 2). Further deletions within this N-terminal region defined aa
8–17 as critical for this function. Deletion of 8–17 residues removed
the sequence RRNL that matched the Cy box (zRxL) defined in
higher eukaryotes as a sequence that mediates binding to the cyclin
subunit of CDKs (57–60). However, a smaller deletion comprising
this sequence (D13–17, RRNLF) had no effect, indicating that the
upstream sequence is required. All of the CDC6 N-terminal mu-
tants (containing wild-type K114), including the point mutants
(below), were able to efficiently complement a deletion of CDC6
when using a plasmid-based assay and had no discernable growth
defects. This was expected, because the N-terminal 50 aa of Cdc6p
are nonessential.
Cdc6p contains three consensus Cdc28p kinase phosphoryla-
tion sites within the N terminus at positions 7, 23, and 43. All
three serine and threonine residues were changed to alanine.
This triple mutant (TTS) was unable to arrest in mitosis and
accumulated with fractional DNA content (Fig. 2). However, no
single phosphorylation site was essential for this activity, because
the individual point mutants still maintained the 1C DNA arrest.
(The first deletion of residues 2–7 removes the first Cdc28p
phosphorylation site, T7.) From an analysis of all possible double
site mutants, the first residue was the most critical because the
T7A T23A double mutant accumulated with fractional DNA
content, the T7A S43A mutant did so partially, and the T23A
Fig. 1. Cells expressing cdc6KE arrest after entry into mitosis. (A) FACS profile
of YB504 (MET3-CDC6 cdc6KE) showing accumulation of cells with 1C DNA
content after repression of wild-type MET3-CDC6. (B) Budding index of K4055
(MET3-CDC6 Dcdc6) and YB504 (MET3-CDC6 cdc6KE) after repression of wild-
type MET3-CDC6. (C) Tubulin immunofluorescence of YB504 at 5-h time point.
The Inset shows that these cells accumulate with long spindles. (D) Viability
curve of YB504 and K4055 following shut-off of CDC6.
Fig. 2. Summary of CDC6 mutational analysis. The sequence of the N-
terminal 50 aa is shown at the top. Cells expressing cdc6KE containing the
indicated N-terminal mutation were grown to early exponential phase. Then
wild-type MET3-CDC6 was repressed by the addition of methionine, samples
were taken every hour for 6 h and scored by FACS for the accumulation of
fractional (0.5C) DNA content. All of the mutants were tested (except DN43)
and found to efficiently complement a CDC6 deletion.
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S43A mutant still arrested with a 1C DNA content. Further-
more, the double mutant T7A D13–17 deletion still arrested in
mitosis, again indicating that aa 8–12 were also critical for the
arrest. These data suggest that mutation of two separate regions
of Cdc6p can abrogate the mitotic arrest: the Cdc28p consensus
phosphorylation sites and a short 10-aa sequence from residues
8–17. The sequences may function together to recruit a factor
that mediates the arrest.
Increasing Cdc28pyClb Kinase Levels Can Overcome the Mitotic Arrest
Caused by cdc6KE. Because the mutational analysis suggested that
a CDK interaction at the N terminus might be important for the
mitotic arrest, we next examined the effect of overproducing
various factors that affect Cdc28p activity (Fig. 3A). Cells
containing MET3-CDC6, cdc6KE, and various plasmids capable
of overproducing CLN1, CDC4, or CLB5 and a vector control
were grown in raffinose medium lacking methionine. At an early
exponential phase of growth, methionine and galactose were
added to the medium to both repress the wild-type copy of CDC6
and to induce expression of the respective genes. Time points
were taken every 2 h for 8 h. Neither the vector control nor
expression of CLN1 or CDC4 could overcome the mitotic arrest.
We also tried Gal expression of CLN2; however, this in itself was
lethal to the cells and greatly broadened the 1C and 2C DNA
peaks by FACS. In contrast, Gal-induced expression of CLB5
overcame the mitotic arrest, indicating that increasing Cdc28p-
Clb5p kinase levels reversed the inhibitory effect of Cdc6KEp on
mitosis.
Because Sic1p is an inhibitor of Cdc28p-Clb kinase but not
Cdc28p-Cln kinase (33, 44), we constructed a strain containing
sic1D MET3-CDC6 cdc6KE(YB777). When the wild-type CDC6
was shut off in these cells lacking SIC1, they also underwent a
reductional mitosis (Fig. 3B). Transformation of an ARS CEN
plasmid containing wild type SIC1 into the sic1D strain (YB777)
restored the ability to block entry into mitosis and also the
normal growth properties of the strain (data not shown). This
observation further indicates that increasing Cdc28p-Clb kinase
activity can overcome the mitotic arrest induced by cdc6KE cells
that have failed to initiate DNA replication.
Mitotic Inhibition by Cdc6KEp Is Correlated with Binding to Cdc28p. It
has been reported that Cdc6p interacts with Cdc28p and inhibits
its kinase activity (55). Furthermore, it was reported that this
Cdc28p interaction is mediated by the N-terminal ’50 aa of
Cdc6p (55). Because the mutational analysis and genetic data
suggested that Cdc6p might inhibit mitosis through an interaction
with Cdc28p-Clb kinase, we tested whether wild-type Cdc6p and
the two mutants that failed to arrest in mitosis could coimmuno-
precipitate Cdc28p. It was difficult to detect binding to Cdc28p after
immunoprecipitation of HA3-Cdc6p from yeast cells, but another
experimental approach was informative. HA epitope-tagged ver-
sions of wild-type Cdc6p or the two mutants were produced in Sf9
insect cells by using recombinant baculoviruses. The HA-Cdc6p
was immunoprecipitated under stringent salt conditions and the
immunoprecipitates washed extensively. This efficient purification
yielded very few contaminating insect cell proteins. The immuno-
precipitates were then mixed with wild-type yeast whole cell extracts
and, after a further 2-h incubation, the presence of Cdc28p was
examined by immunoblotting (Fig. 4).
Similar amounts of wild-type Cdc6p and the two mutants were
recovered in the immunoprecipitates (Fig. 4 Upper). Fig. 4 Lower
shows a Western blot for Cdc28p. Although the wild-type Cdc6p
protein coimmunoprecipitated Cdc28p, as reported (55), both of
the mutants that fail to arrest in mitosis (TTS and D8–17) produced
proteins that were defective in coimmunoprecipitating Cdc28p
(Fig. 4 Lower). Together with the genetic data presented above,
these results suggest that a Cdc6p–Cdc28p interaction is important
in restraining mitosis in the absence of DNA replication initiation.
This could be through Cdc6p phosphorylation, binding of the
Cdc28p–cyclin, inhibition of Cdc28p–cyclin activity, or all three.
Cells Expressing cdc6KE Activate S Phase Cdc28-Clbs on Schedule
During Passage Through G1. Cells in G1 that do not have active
Cdc28p-Clb kinase, but have activated Cdc28-Cln kinase, have a
multibudded phenotype. In contrast, cells that have not activated
Cdc28p-Cln kinase arrest as unbudded cells. Because cells
expressing only cdc6KE arrested with a dumb-bell morphology, it
is likely that they had activated Cdc28p-Clb5p during passage
through G1, even though replication initiation had not occurred.
We sought an independent confirmation that Cdc28p-Clb5p was
activated normally and sought a marker for Cdc28p-Clb5p
activation during G1. Orc6p was a good candidate because it is
phosphorylated as cells initiate DNA synthesis, and dephospho-
rylated as cells exit mitosis and enter G1 (65). Furthermore,
Orc6p phosphorylation required the ORC6 Cdc28p consensus
phosphorylation sites (65), but it was not known whether
Cdc28p-Cln or -Clb kinases were responsible.
To determine whether CLB5 or CLB6 was responsible for the
Orc6p phosphorylation as cells entered S phase, the timing of
Orc6p phosphorylation in wild-type and Dclb5 clb6 cells was
compared after a synchronous release from an alpha factor-
mediated G1 arrest. Cdc28p-Cln kinase is known to be activated
Fig. 3. Increasing Cdc28p-Clb kinase activity abrogates the mitotic block. (A)
YB504 (MET3-CDC6 cdc6KE) was transformed with vector (yCP50) or GAL
expression plasmids for CLN1, CDC4, or CLB5 and grown to early exponential
phase in minimal raffinose (2%) medium lacking uracil and methionine.
Galactose (2%) and methionine (2 mM) were added at time 0 and samples
were taken to analyze DNA content every 2 h for 8 h. (B) FACS profiles showing
that deletion of SIC1 also allows cdc6KE cells to go through a reductional
mitosis. These cells were grown in SCM medium lacking methionine. Methi-
onine (2 mM) was added at time 0 and cells were processed for FACS analysis
at the indicated times. K4055 (MET3-CDC6 Dcdc6), YB504 (MET3-CDC6 cdc6KE),
YB777 (MET3-CDC6 cdc6KE Dsic1).
Fig. 4. Cdc28p is coimmunoprecipitated with wild-type Cdc6p, but not the
two mutants (TTS and D8–17) that go through a reductional mitosis. (Upper)
Cdc6p following immunoprecipitation by silver staining. (Lower) Western blot
for Cdc28p. Experimental details are described in Materials and Methods.
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on schedule in the Dclb5 clb6 cells; however, there is an ’30-min
delay in the initiation of DNA replication because of a failure to
activate Cdc28p-Clb5p and -Clb6p kinases (31, 32). Under these
circumstances, initiation is thought to be dependent on the later
Cdc28p-Clb3p and -Clb4p kinases. At the alpha factor arrest, Orc6p
was in the dephosphorylated form in the two strains (Fig. 5A).
Orc3p was shown as a loading control. Orc6p was phosphorylated
at 30 min after release in the wild-type strain, but was significantly
delayed to 60 min in the Dclb5 clb6 mutant. FACS analysis indicated
that the Dclb5 clb6 strain also delayed entry into S phase relative to
the wild type by 30 min (data not shown), as reported (32). These
results suggest that Clb5p and Clb6p were required for the phos-
phorylation of Orc6p before S phase. Cdc6p bound to chromatin 20
min after release from the alpha factor arrest and was removed by
30 min in both the wild-type and Dclb5 clb6 strains, indicating that
Cdc28p-Clb5p and -Clb6p kinases were not required for either
Cdc6p binding or removal from the chromatin.
Using Orc6p phosphorylation as a marker, we then tested
whether Clb5p and Clb6p were activated on schedule in cells that
were transiting G1-expressing cdc6KE as compared with cells
expressing wild-type Cdc6p. Cells were synchronized in late
mitosis by using the dbf2-1 mutation. While arrested, the wild-
type MET3-CDC6 gene was repressed by the addition of methi-
onine for 30 min and the cells were allowed to enter G1 at the
permissive temperature for dbf2-1, expressing either wild-type
CDC6 or cdc6KE from the endogenous CDC6 promoter. Orc6p
was dephosphorylated within 10 min of release and was rephos-
phorylated beginning at 30 min in both strains (Fig. 5B), thus the
Cdc28p-Clb5p and -Clb6p were activated in both strains at the
same time. The wild-type cells passed through mitosis and
entered G1 phase again during the 105–120-min interval as
evidenced by the dephosphorylation of Orc6p (Fig. 5B). How-
ever, the cdc6KE cells arrested with a 1C DNA content by FACS
(data not shown) and Orc6p remained phosphorylated. These
results demonstrated that Cdc28p-Clb5p and -Clb6p kinases
were activated in the cdc6KE mutant during passage through G1,
consistent with the large-budded arrest phenotype of this strain.
Furthermore, cells actually exited mitosis from the dbf2-1 arrest
point after shutting off wild-type CDC6 and expressing only
cdc6KE, suggesting that the Cdc6KEp mitotic block occurred
earlier than the DBF2 execution point.
Sic1p Regulates Cdc28–Cyclin Interaction with ORC. Because Orc1p,
Orc2p, and Orc6p contain Cdc28p phosphorylation sites and are
phosphorylated in vitro by purified Cdc28p-Clb5p kinase (data not
shown and Fig. 6C), we tested whether ORC could also physically
interact with Cdc28p kinase. Baculovirus expressing ORC and
either Cdc28p alone or Cdc28p together with Cln2p, Clb1p, Clb5p,
or Clb6p were co-infected into Sf9 cells. Soluble Sf9 extracts were
made as described (7) and ORC protein was immunoprecipitated
by using a mixture of monoclonal antibodies against the ORC
subunits. The IP was separated on SDSyPAGE gels and then tested
for coimmunoprecipitation of Cdc28p by Western blotting. Cdc28p
was coimmunoprecipitated with ORC no matter what cyclin sub-
unit was coexpressed and even in the absence of any cyclin subunit
(Fig. 6B, lanes 1, 3, and 5, and data not shown). Cdc28–cyclin was
not immunoprecipitated in the absence of ORC protein (Fig. 6A,
lane 6). We additionally verified that each cyclin subunit was being
coimmunoprecipitated together with Cdc28p by making S35-
labeled Cdc28p–cyclin Sf9 extracts as described (7). S35-labeled
extracts were mixed with (nonlabeled) Sf9 extract expressing ORC,
ORC was immunoprecipitated, and after separation on SDSy
PAGE gels, Cdc28–cyclin coimmunoprecipitated only when ORC
protein was also present in the extract (data not shown).
We then tested whether the CDK inhibitor Sic1p could either
interact with ORC or prevent interaction of various Cdc28–cyclin
pairs with ORC. Sic1p could not be coimmunoprecipitated with
ORC (Fig. 6A, lanes 9 and 10). However, coexpression of Sic1p with
ORC and Cdc28–cyclin prevented the interaction of Cdc28p-Clb5p
with ORC (Fig. 6A, lanes 7 and 8, and B, lanes 1 and 2), but not the
interaction of Cdc28p-Cln2p (Fig. 6B, lanes 3 and 4) or Cdc28 (Fig.
6B, lanes 5 and 6) with ORC. This observation is consistent with the
observation that Sic1p interacts with and inhibits Cdc28p-Clb, but
not Cdc28p-Cln kinases.
We tested whether the Cdc28p kinase in the ORC immuno-
precipitates was active. ORC was immunoprecipitated from
baculovirus-infected Sf9 cells expressing ORC alone, ORC plus
Cdc28p, or ORC plus Cdc28p-Clb5p. After extensive washing,
histone H1 kinase activity was measured. Fig. 6C shows that
although no H1 kinase activity was present in the ORC alone IP
or when Cdc28p was also expressed, a very active H1 kinase is
present in the ORC IP when Cdc28p-Clb5p were coexpressed. In
Fig. 5. Orc6p phosphorylation requires CLB5 CLB6 and Orc6p phosphoryla-
tion occurs on schedule in the cdc6KE mutant during passage through G1. (A)
Cells (W303 MATa and W303 MATa Dclb5 clb6) arrested in G1 by using alpha
factor were released into the cell cycle. Samples were taken at the indicated
minutes and processed into soluble and chromatin containing fractions as
described (64). Western blots of the chromatin fractions are shown. (B) MET3-
CDC6 cells also expressing wild-type CDC6 or cdc6KE were arrested in mitosis by
using the dbf2-1 temperature-sensitive mutation (37°C) for 3 h. Methionine
was added 30 min before release at 25°C and samples were taken at the
indicated minutes following shift to 25°C and blotted for Orc6p.
Fig. 6. Cdc28p kinase coimmunoprecipitates with ORC. (A) Sf9 insect cells
were infected with baculoviruses expressing ORC, Cdc28p, Clb5p, and Sic1p in
various combinations. The same amount of ORC was immunoprecipitated in
each case by using monoclonal anti-ORC antibodies when ORC was expressed.
The IPs were blotted for associated proteins: Cdc28p (Upper) and Sic1p (Low-
er). (B) Sic1p prevents the Cdc28p-Clb5p interaction with ORC. Upper and
Lower show Cdc28p Western blots following immunoprecipitation of ORC
from insect cells expressing the indicated proteins, as above. (C) ORC, Cdc28p,
and Clb5p were coexpressed in insect cells in various combinations. ORC was
immunoprecipitated as above and the IPs were tested for H1 kinase activity
following addition of 1 mg H1 and [g-32P]ATP.
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addition, the Orc1p, Orc2p, and Orc6p subunits were phosphor-
ylated by Cdc28-Clb5p in the IP. There was also weak phos-
phorylation of these ORC subunits in the ORC alone and
ORC-Cdc28p IP (Fig. 6C, lanes 1 and 2), probably reflecting the
association of an insect cell kinase. Only these three ORC
subunits contain consensus Cdc28p phosphorylation sites. Orc1p
has one site, Orc2p has six sites, and Orc6p has four sites. Finally,
an ORC–Cdc28p interaction likely also occurs in yeast. Follow-
ing immunoprecipitation of ORC from exponentially growing
yeast, we detected a CDC28-dependent ORC and H1 kinase
activity, because the ORC-associated kinase activity was seen in
wild-type cells but not in cdc28-4 cells (data not shown).
Discussion
We have described mutations within the N-terminal nonessential
domain of Cdc6p that define regions required for the inhibition of
mitosis in the absence of DNA replication initiation. One mutation
deleted a motif that matches the Cy box consensus present in higher
eukaryotic organisms shown to mediate binding to cdk2-cyclinA
(57–60). This Cdc6p deletion mutant also failed to coimmunopre-
cipitate Cdc28p, consistent with it acting as a Cdc28–cyclin inter-
action domain. We have noticed that the CDK inhibitor Sic1p also
contained a match to the Cy motif near the C terminus at positions
260 to 263 (KRRL). A C-terminal deletion analysis of SIC1 found
that the 26 C-terminal aa were required for growth arrest caused by
overproduction of a nondegradable form of Sic1p (M.W. and B.S.,
unpublished data). One essential sequence within these 26 aa was
the Cy motif and similar findings to ours have been published (70).
This data supports the hypothesis that the Cy motif is also present
in budding yeast and mediates interaction with the B-type Cdc28p
complexes, the inhibitory target of Sic1p. Our data, shown in Fig.
6, also demonstrate that Sic1p has an additional function to block
Clb-CDKs from interacting with ORC. Interestingly, the Cdc28p-
Cln2p kinase could still bind ORC in the presence of Sic1p. We
suggest that Sic1p not only ensures a temporal pattern of CDK
activation, but also regulates access of specific CDKs to their key
substrates.
The second mutation that abrogated the mitotic block was a
triple alanine substitution of the three N-terminal Cdc28p
phosphorylation sites in Cdc6p. The corresponding protein was
also defective in coimmunoprecipitating Cdc28p. Because we
were able to overcome the mitotic arrest phenotype by increasing
the amount of Cdc28p-Clb activity, either by overproducing
Clb5p or deleting the Cdc28p-Clb inhibitor SIC1, together this
data suggests that, like Sic1p, Cdc6p plays a role in passage
through mitosis by interaction with Cdc28-Clb kinases.
The CDC6 homologues share a conserved core region shown
by the recently solved crystal structure of an archaeal Cdc6
orthologue to encode a two-domain, ATP-binding module of the
AAA1 family, and a C-terminal winged-helix that may interact
with DNA or other proteins (71). An alignment of human,
Xenopus, S. pombe, and S. cerevisiae CDC6 homologues indicates
very little sequence conservation in their N-terminal regions,
and in fact the N termini have very different lengths. So it was
surprising to find that the alignment showed sequence conser-
vation just covering the ten amino acids from positions 8–17 in
the budding yeast protein. Furthermore, all of the Cdc6 proteins
had CDK consensus phosphorylation sites in their N termini.
Perhaps the mitotic function of this N-terminal domain is
conserved in the various Cdc6 proteins.
Cdc6p may be one component of the previously described
G1–M phase checkpoint that blocks mitosis in the absence of
replication initiation; however, the CDC6-dependent arrest
could be a separate phenomenon. The mitotic arrest seen in the
cdc6KE mutant was RAD53-independent and our data indicated
that another locus in addition to CDC6 was also involved.
An apparent discrepancy with our finding of a mitotic inhib-
itory role for the Cdc6p N terminus is the report that depletion
of Cdc45p also resulted in a reductional mitosis in the absence
of initiation of DNA replication (28). There are several expla-
nations for this finding. One is that not all S. cerevisiae strains
retain the ability to block mitosis in the absence of initiation and
this pathway may be defective in the particular strain used.
Alternatively, the nonfunctional K114E mutation in Cdc6p
might be required to reveal the mitotic arrest, because this
mutant is unable to load the Mcm proteins during late mitosis.
The absence of the preRC may be required for the mitotic block.
Recent studies in Xenopus have suggested that binding of
cyclinE-cdk2 to preRCs is necessary for the initiation of DNA
replication (72). Also, many tumor cells overexpress cyclin E, and
it is known that this circumstance can lead to genetic instability and
inappropriate regulation of S phase (73). It is therefore likely that
inappropriate temporal regulation of CDKs will disrupt the events
that lead to accurate inheritance of the genome. In this paper we
have uncovered additional mechanisms to ensure that cyclin-
dependent kinases are precisely coordinated with the events nec-
essary to lead to initiation of DNA replication. As cells exit mitosis
and proceed through G1 phase, Clb-cyclin kinases are kept inactive
by the combination of an active APC and the presence of CDK
inhibitor Sic1p. We suggest that the Cdc6p on chromatin during the
G1 phase of the cell cycle (12) may also act to inhibit Clb-cyclin
kinase activity as cells exit mitosis, and therefore provide an
opportunity for preRCs to be formed. Paradoxically, Clb-like
CDKs are required in late G1 phase to activate S phase and
initiation of DNA replication at each origin. Cdc6 is located at each
origin because it binds directly to ORC (14). Thus, Cdc6 could
potentially create a local environment in which CDKs would be
prevented from prematurely activating preRCs. We have also
demonstrated that Cln-CDKs can bind to ORC in the presence of
Sic1p, but that Clb-CDKs cannot. Cln-CDKs trigger the destruction
of Cdc6p and Sic1p, thereby removing Cdc6p from origins. In the
absence of Sic1p, the Clb-CDKs then act on preRCs to initiate
DNA replication. Thus, Sic1p acts as a molecular chaperone to
orchestrate temporal-specific CDK function at replication origins.
The presence of Cdc6 at origins during G1 phase also ensures that
cells do not enter into mitosis without having replicated DNA, but
it is clear that additional mechanisms must be operating to ensure
the dependence of mitosis on DNA replication.
Note Added in Proof. Similar conclusions have recently been published
(74). ‘‘Cdc6 cooperates with Sic1 and Hct1 to inactivate mitotic cyclin-
dependent kinases.’’
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